These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31563866)

  • 1. Effect of posterior vitreous detachment on treat-and-extend versus monthly ranibizumab for neovascular age-related macular degeneration.
    Waldstein SM; Coulibaly L; Riedl S; Sadeghipour A; Gerendas BS; Schmidt-Erfurth UM
    Br J Ophthalmol; 2020 Jul; 104(7):899-903. PubMed ID: 31563866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study.
    Kertes PJ; Galic IJ; Greve M; Williams RG; Rampakakis E; Scarino A; Sheidow T
    Ophthalmology; 2019 Jun; 126(6):841-848. PubMed ID: 30677465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
    Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration.
    Mayr-Sponer U; Waldstein SM; Kundi M; Ritter M; Golbaz I; Heiling U; Papp A; Simader C; Schmidt-Erfurth U
    Ophthalmology; 2013 Dec; 120(12):2620-2629. PubMed ID: 23870300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ
    Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
    Sarraf D; London NJ; Khurana RN; Dugel PU; Gune S; Hill L; Tuomi L
    Ophthalmology; 2016 Oct; 123(10):2213-24. PubMed ID: 27566855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration - results from the randomized, phase IIIb OCTAVE study.
    Staurenghi G; Garweg JG; Gerendas BS; Macfadden W; Gekkiev B; Margaron P; Dunger-Baldauf C; Kolar P
    BMC Ophthalmol; 2020 Jan; 20(1):18. PubMed ID: 31918685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
    Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew A; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel D; Desai R;
    JAMA Ophthalmol; 2020 Aug; 138(8):835-842. PubMed ID: 32644148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the Vitreoretinal Interface on the Treatment with Anti-VEGF for Exudative Age-Related Macular Degeneration.
    Gil P; Gil J; Oliveira N; Laíns I; Camilo ENR; Fonseca C; Raimundo M; Cachulo MDL; Silva R
    Ophthalmologica; 2018; 240(1):29-36. PubMed ID: 29734180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of posterior vitreous detachment on the efficacy of anti-vascular endothelial growth factor intravitreal injection for treatment of neovascular age-related macular degeneration.
    Neudorfer M; Fuhrer AE; Zur D; Barak A
    Indian J Ophthalmol; 2018 Dec; 66(12):1802-1807. PubMed ID: 30451182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.
    Wykoff CC; Croft DE; Brown DM; Wang R; Payne JF; Clark L; Abdelfattah NS; Sadda SR;
    Ophthalmology; 2015 Dec; 122(12):2514-22. PubMed ID: 26391465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Holekamp NM; Campochiaro PA; Chang MA; Miller D; Pieramici D; Adamis AP; Brittain C; Evans E; Kaufman D; Maass KF; Patel S; Ranade S; Singh N; Barteselli G; Regillo C;
    Ophthalmology; 2022 Mar; 129(3):295-307. PubMed ID: 34597713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.
    Gale RP; Pearce I; Eter N; Ghanchi F; Holz FG; Schmitz-Valckenberg S; Balaskas K; Burton BJL; Downes SM; Eleftheriadis H; George S; Gilmour D; Hamilton R; Lotery AJ; Patel N; Prakash P; Santiago C; Thomas S; Varma D; Walters G; Williams M; Wolf A; Zakri RH; Igwe F; Ayan F
    Br J Ophthalmol; 2020 Apr; 104(4):493-499. PubMed ID: 31383649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Gune S; Abdelfattah NS; Karamat A; Balasubramanian S; Marion KM; Morgenthien E; Sadda SR
    Ophthalmology; 2020 Apr; 127(4):523-532. PubMed ID: 31718842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. THE INFLUENCE OF VITREOMACULAR ADHESION ON OUTCOMES AFTER AFLIBERCEPT THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    McKibbin MA; Suter CA; Willis TA
    Retina; 2015 Oct; 35(10):1951-6. PubMed ID: 25932561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study.
    Silva R; Berta A; Larsen M; Macfadden W; Feller C; Monés J;
    Ophthalmology; 2018 Jan; 125(1):57-65. PubMed ID: 28893454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.
    Stoller GL; Kokame GT; Dreyer RF; Shapiro H; Tuomi LL
    JAMA Ophthalmol; 2016 May; 134(5):545-553. PubMed ID: 27010625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up.
    Inan S; Baysal Z; Inan UU
    Curr Eye Res; 2019 Aug; 44(8):908-915. PubMed ID: 30909756
    [No Abstract]   [Full Text] [Related]  

  • 20. Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials.
    Khurana RN; Rahimy E; Joseph WA; Saroj N; Gibson A; Vitti R; Berliner AJ; Chu K; Cheng Y; Boyer DS
    Am J Ophthalmol; 2019 Apr; 200():161-168. PubMed ID: 30664844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.